Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 16/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.53 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.53 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.53 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296812 | 0.91 | KRAS (0.56) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL20340580 | 0.90 | KRAS (0.56) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29715195 | 0.90 | KRAS (0.72) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647122 | 0.90 | KRAS (0.72) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765992 | 0.89 | KRAS (0.60) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647072 | 0.89 | KRAS (0.60) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17026609 | 0.89 | KRAS (0.60) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296817 | 0.89 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL21459081 | 0.89 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296825 | 0.88 | KRAS (0.55) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 3439/4885HMOX2 1325/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885EGFR 2207/4885HMOX2 764/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KRAS 242/4885EGFR 2207/4885HMOX2 764/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 3439/4885HMOX2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.